Short answer
CG Oncology, Inc. (CGON) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces CG Oncology’s financial results for quarter ended September 30, 2026.
CG Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces CG Oncology’s financial results for quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed financial results and management commentary for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 net loss $56.9M, or $0.64 per share, versus $43.8M and $0.57 in Q3 2025
- R&D spending rose to $39.2M from $27.9M, reflecting advancing clinical trials, CMC costs and higher headcount
- Cash, equivalents and marketable securities $984.5M, supporting management’s projected operating runway through 2029
- PIVOT-006 Phase 3 topline data expected November 2026, a key efficacy and regulatory catalyst in intermediate-risk and high-grade Ta NMIBC
- BOND-003 and CORE-008 12-month data expected December 2026, with BLA submission completion targeted for Q4 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CG Oncology, Inc. 8-K filings
Get the next CGON 8-K as it lands
Follow CGON for push alerts, or ask the research agent what this filing means.